

CYTEC INDUSTRIES INC/DE/
Form 10-Q
July 28, 2010
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2010

Commission file number 1-12372

CYTEC INDUSTRIES INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	22-3268660 (I.R.S. Employer Identification No).
Five Garret Mountain Plaza Woodland Park, New Jersey (Address of principal executive offices)	07424 (Zip Code)
Registrant's telephone number, including area code (973) 357-3100	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See definition of "accelerated filer, large accelerated filer, and smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Large accelerated filer Accelerated filer Non-accelerated filer Small reporting company
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

There were 49,057,835 shares of common stock outstanding at July 22, 2010.

Table of Contents

CYTEC INDUSTRIES INC. AND SUBSIDIARIES

10-Q Table of Contents

	Page
Part I Financial Information	
Item 1. <u>Consolidated Financial Statements</u>	3
<u>Consolidated Statements of Income</u>	3
<u>Consolidated Balance Sheets</u>	4
<u>Consolidated Statements of Cash Flows</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	23
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	33
Item 4. <u>Controls and Procedures</u>	34
Part II Other Information	
Item 1. <u>Legal Proceedings</u>	35
Item 6. <u>Exhibits</u>	35
<u>Signature</u>	36
<u>Exhibit Index</u>	37

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. CONSOLIDATED FINANCIAL STATEMENTS**

CYTEC INDUSTRIES INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(Dollars in millions, except per share amounts)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2010	2009	2010	2009
Net sales	\$ 873.9	\$ 685.3	\$ 1,660.7	\$ 1,297.3
Manufacturing cost of sales	666.8	603.0	1,290.0	1,100.8
Selling and technical services	50.8	50.6	99.1	100.0
Research and process development	18.4	21.0	36.1	38.9
Administrative and general	33.2	30.8	62.1	60.4
Amortization of acquisition intangibles	9.0	9.4	18.5	18.6
Gain/(loss) on sale of assets	0.0	(1.4)	0.0	0.2
Earnings/(loss) from operations	95.7	(30.9)	154.9	(21.2)
Other expense, net	1.7	0.1	2.0	3.3
Net loss on early extinguishment of debt	0.0	0.0	0.7	0.0
Equity in earnings of associated companies	0.3	0.3	0.4	0.5
Interest expense, net	7.9	5.1	16.1	10.7
Earnings/(loss) before income taxes	86.4	(35.8)	136.5	(34.7)
Income tax provision/(benefit)	24.0	(11.4)	48.4	(10.4)
Net earnings/(loss)	62.4	(24.4)	88.1	(24.3)
Less: Net earnings attributable to noncontrolling interests	(0.6)	(0.4)	(1.5)	(0.6)
Net earnings/(loss) attributable to Cytec Industries Inc.	\$ 61.8	\$ (24.8)	\$ 86.6	\$ (24.9)
Earnings/(loss) per share attributable to Cytec Industries Inc.				
Basic earnings/(loss) per common share	\$ 1.26	\$ (0.52)	\$ 1.76	\$ (0.52)
Diluted earnings/(loss) per common share	\$ 1.24	\$ (0.52)	\$ 1.75	\$ (0.52)
Dividends per common share	\$ 0.0125	\$ 0.0125	\$ 0.025	\$ 0.1375

See accompanying Notes to Consolidated Financial Statements

Table of Contents

CYTEC INDUSTRIES INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Dollars in millions, except per share amounts)

	June 30, 2010	December 31, 2009
Assets		
Current assets		
Cash and cash equivalents	\$ 311.5	\$ 261.7
Trade accounts receivable, less allowance for doubtful accounts of \$5.1 and \$6.6 in 2010 and 2009, respectively	455.0	374.2
Other accounts receivable	51.1	58.4
Inventories	389.4	351.9
Deferred income taxes	36.1	41.3
Currency swap receivable	0.0	34.4
Other current assets	21.9	19.0
Total current assets	1,265.0	1,140.9
Investment in associated companies	18.2	21.5
Plants, equipment and facilities, at cost	2,274.3	2,310.0
Less: accumulated depreciation	(1,142.1)	(1,133.8)
Net plant investment	1,132.2	1,176.2
Acquisition intangibles, net of accumulated amortization of \$214.6 and \$214.8 in 2010 and 2009, respectively	344.3	399.5
Goodwill	659.7	701.9
Deferred income taxes	14.0	11.9
Other assets	107.8	107.5
Total assets	\$ 3,541.2	\$ 3,559.4
Liabilities		
Current liabilities		
Accounts payable	\$ 360.5	\$ 276.4
Short-term borrowings	9.1	10.4
Current maturities of long-term debt	16.8	16.7
Accrued expenses	198.8	202.2
Income taxes payable	25.9	19.2
Currency swap payable	13.0	45.3
Deferred income taxes	2.1	5.2
Total current liabilities	626.2	575.4
Long-term debt	643.3	658.4
Pension and other postretirement benefit liabilities	347.8	388.8
Other noncurrent liabilities	254.3	309.7
Deferred income taxes	87.2	64.0

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Stockholders equity

Preferred stock, 20,000,000 shares authorized; none issued and outstanding	0.0	0.0
Common stock, \$.01 par value per share, 150,000,000 shares authorized; issued 49,316,913	0.5	0.5
Additional paid-in capital	448.2	451.0
Retained earnings	1,208.6	1,123.2
Accumulated other comprehensive (loss)/gain	(63.3)	16.0
Treasury stock, at cost, 285,568 shares in 2010 and 594,134 shares in 2009	(16.2)	(31.8)
Total Cytec Industries Inc. stockholders equity	1,577.8	1,558.9
Noncontrolling interests	4.6	4.2
Total equity	1,582.4	1,563.1
Total liabilities and stockholders equity	\$ 3,541.2	\$ 3,559.4

See accompanying Notes to Consolidated Financial Statements

Table of Contents

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in millions)

	Six Months Ended June 30,	
	2010	2009
Cash flows provided by (used in) operating activities		
Net earnings/(loss)	\$ 88.1	\$ (24.3)
Noncash items included in net earnings/(loss):		
Depreciation	52.3	55.2
Amortization	22.5	21.7
Share-based compensation	5.6	4.1
Deferred income taxes	19.6	(21.8)
Gain on sale of assets	(2.3)	(0.2)
Loss on early extinguishment of debt	0.7	0.0
Unrealized loss/(gain) on derivative instruments	2.8	(7.4)
Other	0.3	0.5
Changes in operating assets and liabilities:		
Trade accounts receivable	(109.7)	49.2
Other receivables	5.8	27.7
Inventories	(56.6)	149.4
Other assets	1.1	(14.9)
Accounts payable	110.0	(0.4)
Accrued expenses	5.1	9.8
Income taxes payable	14.2	(11.1)
Other liabilities	(35.1)	(7.1)
Net cash provided by operating activities	124.4	230.4
Cash flows (used in) provided by investing activities		
Additions to plants, equipment and facilities	(55.6)	(116.3)
Net proceeds received on sale of assets	1.7	7.0
Net cash used in investing activities	(53.9)	(109.3)
Cash flows provided by (used in) financing activities		
Proceeds from long-term debt	0.0	108.0
Payments on long-term debt	(15.5)	(200.3)
Change in short-term borrowings, net	(1.5)	(17.8)
Cash dividends	(2.5)	(6.5)
Proceeds from the exercise of stock options	8.6	1.5
Excess tax benefits from share-based payment arrangements	0.8	0.0
Net cash used in financing activities	(10.1)	(115.1)
Effect of currency rate changes on cash and cash equivalents	(10.6)	0.9
Increase in cash and cash equivalents	49.8	6.9

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Cash and cash equivalents, beginning of period	261.7	55.3
Cash and cash equivalents, end of period	\$ 311.5	\$ 62.2

See accompanying Notes to Consolidated Financial Statements

Table of Contents

CYTEC INDUSTRIES INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Currencies in millions, except per share amounts, unless otherwise indicated)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q and accounting principles generally accepted in the United States of America (U.S. GAAP) for interim reporting. Certain information and footnote disclosures normally included in our annual financial statements have been condensed or omitted pursuant to such rules and regulations. Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. In the opinion of management, these financial statements include all normal and recurring adjustments necessary for a fair presentation of the financial position and the results of our operations and cash flows for the interim periods presented. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year. The financial statements should be read in conjunction with the Consolidated Financial Statements and Notes to the Consolidated Financial Statements contained in the Company's 2009 Annual Report on Form 10-K. Unless indicated otherwise, the terms Company , Cytec , we , us and our each refer collectively to Cytec Industries Inc. and its subsidiaries.

2. DIVESTITURES

In the first quarter of 2009, we sold certain of our European polyurethane product line assets for cash proceeds totaling \$5.7 and recognized a pre-tax gain on sale of \$1.6 (\$1.0 after-tax). The gain is recorded in net gain/(loss) on sale of assets in the accompanying statements of income.

Also in the first quarter of 2009, we decided to pursue strategic alternatives for our polyurethane product line assets in Asia. Accordingly, we revised the estimated remaining useful life of the assets to reflect the period we expected to continue to use the assets and recognized incremental depreciation expense in the first quarter of 2009 of \$1.2 which is recorded in manufacturing cost of sales. We also recorded a charge of \$0.4 during the first quarter of 2009 for additional costs that were incurred as a result of this decision, which are recorded in selling and technical services. In the second quarter of 2009, we sold our polyurethane product line assets in Asia for \$1.8 of which \$1.2 was received in cash and \$0.6 represents a promissory note from the purchaser. The net loss of \$1.4 resulting from this sale is recorded in gain/(loss) on sale of assets in the accompanying statements of income.

3. RESTRUCTURING OF OPERATIONS

In accordance with our policy, restructuring costs are included in our corporate unallocated operating results for segment reporting purposes consistent with management's view of its businesses.

Table of Contents

Aggregate restructuring charges/(credits) included in the statements of income were recorded by line item as follows:

	For the three months ended June 30,		For the six months ended June 30,	
	2010	2009	2010	2009
Manufacturing cost of sales	\$ 5.0	\$ 23.9	\$ 4.8	\$ 26.0
Selling and technical services	0.0	4.0	(0.1)	4.5
Research and process development	0.0	3.4	0.0	3.6
Administrative and General	(0.5)	2.9	(0.6)	3.3
Other expense, net	0.3	0.0	0.3	0.0
Total	\$ 4.8	\$ 34.2	\$ 4.4	\$ 37.4

Details of 2010 restructuring initiatives are as follows:

In May 2010, we approved plans to exit the production of certain phosphorus derivative products at our Mt. Pleasant, Tennessee facility. These plans resulted in a restructuring charge of \$5.1 of which \$0.4 relates to the severance of 12 positions, \$1.2 relates to assets write-off, and \$3.5 relates to decommissioning activities. The remaining reserve of \$3.7 at June 30, 2010 is expected to be paid in 2010.

Details of 2009 restructuring initiatives are as follows:

In 2009, we initiated restructuring actions across all segments and corporate functions. These actions were taken in response to the downturn in the global economy, which especially impacted the automotive, construction and general industrial markets that we serve, and led to a significant reduction in our sales and operating profitability. The following summarizes the details of the restructuring initiatives launched in 2009, which resulted in \$91.9 of restructuring charges for the year ended December 31, 2009.

We launched restructuring initiatives at several of our Specialty Chemical manufacturing locations, which resulted in restructuring charges totaling \$70.4 of which \$40.4 is associated with severance and other employee benefits and \$30.0 is associated with asset write-downs and accelerated depreciation. The manufacturing locations impacted by these initiatives are as follows:

Closure of our manufacturing facility in La Llagosta, Spain and transfer of the manufacturing of most of the liquid coating resins products produced at the site to our facility in Werndorf, Austria.

Transfer the manufacturing of our powder coating resins product line from Drogenbos, Belgium to our manufacturing facility in Bassano, Italy and consolidate or eliminate supply chain, sales, marketing and administrative functions at the site.

Transfer the manufacturing of certain liquid coating resins products from our Hamburg, Germany site to our facility in Werndorf, Austria and consolidate or eliminate certain manufacturing, supply chain, and administrative functions at the site.

Conversion of our manufacturing facility in Antofagasta, Chile into a blending and distribution facility to support the Mining business and eliminate manufacturing functions at the site.

Closure of our manufacturing facility in Bogota, Colombia.

The above manufacturing restructuring initiatives include the elimination of 366 positions.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

We launched restructuring initiatives across our Engineered Materials segment in response to inventory destocking by parts manufacturers that supply large commercial aircraft manufacturers as well as a sharper than expected decline in business and regional jet production rates. These initiatives resulted in \$4.4 of restructuring expenses for severance and employee benefits related to the elimination of 239 positions.

-7-

Table of Contents

We launched several initiatives throughout 2009 in our Specialty Chemical segments and corporate functions across sales, marketing, manufacturing, supply chain, research and development, and administrative functions, including our initiative to establish a shared services center. These initiatives resulted in \$17.1 of charges related to severance and employee benefits associated with the elimination of 393 positions.

For the three and six months ended June 30, 2010, we recorded net favorable adjustments of \$0.3 and \$0.7, respectively, related to our 2009 restructuring initiatives. All of the aforementioned initiatives were substantially complete as of December 31, 2009, with the exception of the shared services initiative, which is expected to be completed in waves throughout 2010 and 2011.

The remaining reserve at June 30, 2010 of \$14.6 relating to 2009 restructuring initiatives is expected to be paid through 2012.

Details of 2008 restructuring initiatives are as follows:

In 2008, as a cost reduction initiative and to align our cost structure to the declining demand environment at that time, we decided to restructure certain activities of our Coating Resins segment. These initiatives resulted in restructuring charges of \$11.1 for the twelve months ended December 31, 2008, which primarily relate to severance for 93 eliminated positions. These initiatives were completed in 2008. In 2009, the remaining balance of \$0.9 was reversed as a result of actual costs being less than our forecast. All costs were paid in full as of December 31, 2009.

Details of 2007 restructuring initiatives are as follows:

In 2007, we initiated restructuring actions across our Specialty Chemicals segments to exit several mature product lines manufactured at our Willow Island, West Virginia and Wallingford, Connecticut facilities. As a result, we recorded total restructuring charges of \$7.0 in 2007 and 2008. These initiatives were completed in 2008. In 2009, the remaining balance of \$0.6 was reversed as a result of actual costs being less than our forecast. All costs were paid in full as of December 31, 2009.

	2007 Restructuring Initiatives	2008 Restructuring Initiatives	2009 Restructuring Initiatives	2010 Restructuring Initiatives	Total	
Balance December 31, 2008	\$ 2.0	\$ 4.3	\$ 0.0	\$ 0.0	\$ 6.3	
2009 charges/(credits)	(0.6)	(0.9)	91.9	0.0	90.4	
Non-cash items	0.0	0.0	(30.6)	(1)	(30.6)	
Cash payments	(1.4)	(3.3)	(31.0)	0.0	(35.7)	
Currency translation adjustments	0.0	(0.1)	1.3	0.0	1.2	
Other adjustments	0.0	0.0	(0.8)	(2)	(0.8)	
Balance December 31, 2009	\$ 0.0	\$ 0.0	\$ 30.8	\$ 0.0	\$ 30.8	
1st quarter charges/(credits)	0.0	0.0	(0.4)	0.0	(0.4)	
Cash payments	0.0	0.0	(10.9)	0.0	(10.9)	
Currency translation adjustments	0.0	0.0	(0.9)	0.0	(0.9)	
Balance March 31, 2010	\$ 0.0	\$ 0.0	\$ 18.6	\$	\$ 18.6	
2nd quarter charges/(credits)	0.0	0.0	(0.3)	5.1	4.8	
Non-cash items	0.0	0.0	0.0	(1.2)	(3)	(1.2)
Cash payments	0.0	0.0	(2.2)	(0.2)	(2.4)	
Currency translation adjustments	0.0	0.0	(1.5)	0.0	(1.5)	
Balance June 30, 2010	\$ 0.0	\$ 0.0	\$ 14.6	\$ 3.7	\$ 18.3	

- (1) Represents accelerated depreciation of plant assets and impairment of the land at our facility in La Llagosta, Spain.
- (2) Represents a reclass of an environmental related restructuring accrual to environmental liabilities.
- (3) Represents write-offs of inventories and construction in progress at our Mt. Pleasant, Tennessee facility.

Table of Contents**4. SHARE-BASED COMPENSATION**

The fair value of each option or stock-settled share appreciation right (stock-settled SARS) award is estimated on the date of grant using a binomial-lattice option valuation model. Stock-settled SARS are economically valued the same as stock options. The binomial-lattice model takes into account variables such as volatility, dividend yield, and risk-free interest rate. In addition, the binomial-lattice model considers the contractual term of the option, the probability that the option will be exercised prior to the end of its contractual life, and the probability of termination or retirement of the option holder in computing the value of the option. The assumptions for the six months ended June 30, 2010 and 2009 are noted in the following table:

	2010	2009
Expected life (years)	6.1	6.7
Expected volatility	43.3%	48.2%
Expected dividend yield	0.19%	2.23%
Risk-free interest rate	3.75%	2.7%
Weighted-average fair value per option	\$16.49	\$8.58

The expected life of options granted represents the period of time that options granted are expected to be outstanding. Expected volatilities are based on the combination of implied market volatility and our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. As share-based compensation recognized in the consolidated statement of income is based on awards ultimately expected to vest, we incorporate the probability of pre-vesting forfeiture in determining the number of expected vested options. The forfeiture rate is based on the historical forfeiture experience and prospective analysis.

Stock Award and Incentive Plan:

The 1993 Stock Award and Incentive Plan (the 1993 Plan) provides for grants of a variety of awards, such as stock options (including incentive stock options and nonqualified stock options), non-vested stock (including performance stock), SARS (including those settled with common shares) and deferred stock awards and dividend equivalents. At June 30, 2010, there were approximately 2,400,000 shares reserved for issuance under the 1993 Plan, and 3,600,000 shares underlying all outstanding share-based compensation grants.

We have utilized the stock option component of the 1993 Plan to provide for the granting of nonqualified stock options and stock-settled SARS with an exercise price at 100% of the market price on the date of the grant. Options and stock-settled SARS are generally exercisable in installments of one-third per year commencing one year after the date of grant and annually thereafter, with contract lives of generally 10 years from the date of grant.

A summary of stock options and stock-settled SARS activity for the six months ended June 30, 2010 is presented below.

	Number of Units	Weighted Average Exercise Price Per Unit	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Options and Stock-Settled SARS Activity:				
Outstanding at January 1, 2010	3,822,502	\$ 39.67		
Granted	457,990	37.71		
Exercised	(268,917)	31.56		
Forfeited	(775,991)	39.78		
Outstanding at June 30, 2010	3,235,584	\$ 40.04	6.2	\$ 18.2
Exercisable at June 30, 2010	2,248,504	\$ 42.85	5.0	\$ 10.2

Table of Contents

	Number of Units	Weighted Average Grant Date Fair Value Per Unit
Nonvested Options and Stock- Settled SARS:		
Nonvested at January 1, 2010	1,093,706	\$ 12.84
Granted	457,990	16.49
Vested	(518,838)	14.64
Forfeited	(45,778)	14.47
Nonvested at June 30, 2010	987,080	\$ 13.50

During the six months ended June 30, 2010, we granted 457,990 stock options. The weighted-average grant-date fair value of the stock-settled SARS and stock options granted during the six months ended June 30, 2010 and 2009 was \$16.49 and \$8.58 per share, respectively. Total pre-tax compensation cost related to stock option and stock-settled SARS was \$2.1 and \$1.7 during the three months ended June 30, 2010 and 2009, respectively, and \$4.0 and \$3.5 during the six months ended June 30, 2010 and 2009, respectively. The total intrinsic value of stock options and stock-settled SARS exercised during the six months ended June 30, 2010 and 2009 was \$3.5 and \$0.1, respectively. Treasury shares have been utilized for stock option and stock-settled SARS exercises. The total fair value of stock options and stock-settled SARS vested during the six months ended June 30, 2010 and 2009 was \$7.6 and \$9.7, respectively.

As of June 30, 2010, there was \$9.1 of total unrecognized compensation cost related to stock options and stock-settled SARS. That cost is expected to be recognized over a weighted-average period of 1.3 years as the majority of our awards vest over three years. Compensation cost related to stock options and stock-settled SARS capitalized in inventory as of June 30, 2010 and December 31, 2009 was approximately \$0.3 and \$0.2, respectively.

Cash received (for stock options only) and the tax (deficiency)/benefit realized from stock options and stock settled SARS exercised and deferred shares issued were \$8.6 and \$1.0 for the six months ended June 30, 2010 and \$1.5 and \$(0.2) for the six months ended June 30, 2009, respectively. Cash used to settle cash-SARS exercises for the six months ended June 30, 2010 was immaterial at less than \$0.1. There were no cash-SARS exercises for the six months ended June 30, 2009. The liability related to our cash-settled SARS was \$2.5 at June 30, 2010 and \$1.7 at December 31, 2009.

As provided under the 1993 Plan, we have also issued non-vested stock, non-vested stock units, and performance stock. Non-vested stock and stock units are subject to certain restrictions on ownership and transferability that lapse upon vesting. Performance share payouts are based on the attainment of certain financial performance objectives and may vary depending on the degree to which the performance objectives are met. During the six months ended June 30, 2010, we granted 60,525 units of non-vested stock units. The total amount of share-based compensation expense recognized for non-vested shares, non-vested units, and performance stock for three months ended June 30, 2010 and 2009 was \$0.5 and \$0.2, respectively, and for six months ended June 30, 2010 and 2009 was \$0.9 and \$0.4, respectively.

As of June 30, 2010 and December 31, 2009, our additional paid-in capital pool (APIC Pool) which represents excess tax benefits available to absorb potential future tax deficiencies was \$68.1 and \$69.9, respectively.

5. EARNINGS PER SHARE (EPS)

Basic earnings/(loss) per common share excludes dilution and is computed by dividing net earnings/(loss) available to common stockholders by the weighted-average number of common shares outstanding (which includes shares outstanding, less performance and non-vested shares for which vesting criteria have not been met) plus deferred stock awards, weighted for the period outstanding. Diluted earnings per common share is computed by dividing net earnings available to common stockholders by the sum of the weighted-average number of common shares outstanding for the period adjusted (i.e., increased) for all additional common shares that would have been outstanding if potentially dilutive common shares had been issued and any proceeds of the issuance had been used to repurchase common stock at the average market price during the period. Under this method, an increase in the fair market value of the Company's stock can result in a greater dilutive effect from potentially dilutive common shares. The proceeds are assumed to be the sum of the amount to be paid to the Company upon exercise of options, the amount of compensation cost attributed to future services and not yet recognized, and the amount of income taxes that would be credited to or deducted from capital upon exercise.

Table of Contents

The following table sets forth the computation of basic and diluted earnings per common share for the three and six months ended June 30 (in thousands, except net earnings/(loss) in millions and per share amounts):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Numerator:				
Net earnings/(loss) attributable to Cytec Industries, Inc.	\$ 61.8	\$ (24.8)	\$ 86.6	\$ (24.9)
Denominator:				
Weighted average shares outstanding	49,226	48,154	49,152	47,818
Effect of dilutive shares:				
Options and stock-settled SARS	366	0	378	0
Non-vested shares and units	48	0	45	0
Diluted average shares outstanding	49,640	48,154	49,575	47,818
Basic earnings/(loss) per common share	\$ 1.26	\$ (0.52)	\$ 1.76	\$ (0.52)
Diluted earnings/(loss) per common share	\$ 1.24	\$ (0.52)	\$ 1.75	\$ (0.52)

Since the results for the three and six months ended June 30, 2009 were a loss, all per share calculations are performed using the same denominator, as the loss available to common stockholders renders all potential common shares anti-dilutive.

The following table sets forth the anti-dilutive shares/units excluded from the above calculation because their inclusion would have had an anti-dilutive effect on earnings per share (in thousands):

	Six Months Ended June 30,	
	2010	2009
Options	722	2,704
Stock-Settled SARS	1,230	1,464
Non-vested shares/units	11	12
Total	1,963	4,180

6. INVENTORIES

Inventories consisted of the following:

	June 30, 2010	December 31, 2009
Finished goods	\$ 258.5	\$ 234.8
Work in progress	29.8	33.6
Raw materials and supplies	101.1	83.5
Total inventories	\$ 389.4	\$ 351.9

Table of Contents**7. DEBT**

Long-term debt, including the current portion, consisted of the following:

	June 30, 2010		December 31, 2009	
	Face	Carrying Value	Face	Carrying Value
Five-Year Revolving Credit Line Due June 2012	\$ 0.0	\$ 0.0	\$ 0.0	\$ 0.0
5.5% Notes Due October 1, 2010	15.4	15.4	15.4	15.4
4.6% Notes Due July 1, 2013	142.4	142.9	157.2	157.8
6.0% Notes Due October 1, 2015	250.0	249.7	250.0	249.6
8.95% Notes Due July 1, 2017	250.0	249.4	250.0	249.4
Other	2.7	2.7	2.9	2.9
	\$ 660.5	\$ 660.1	\$ 675.5	\$ 675.1
Less: Current maturities	(16.8)	(16.8)	(16.7)	(16.7)
Long-term Debt	\$ 643.7	\$ 643.3	\$ 658.8	\$ 658.4

All of the outstanding notes are unsecured and may be repaid in whole or in part, at our option at any time subject to a prepayment adjustment.

During the first quarter of 2010, we repurchased portions of our 4.6% notes due July 1, 2013 with a total carrying value of \$14.5 for a total purchase price of \$15.2 including accrued interest, resulting in a loss of \$0.7. Net loss from our debt repurchases is included in net loss on early extinguishment of debt in the accompanying statement of income.

During the second quarter of 2010, we repurchased a portion of our 4.6% notes due July 1, 2013 with a total carrying value of \$0.3 for a total purchase price of \$0.3 including accrued interest, resulting in a loss of less than \$0.1.

On July 6, 2009 we sold \$250.0 aggregate principal amount of 8.95% senior unsecured notes due July 1, 2017, which resulted in \$247.7 in net proceeds after original issue discount and underwriting fees. In addition, on June 30, 2009, we commenced offers to purchase our 5.5% notes due October 1, 2010 and our 4.6% notes due July 1, 2013. In July 2009, we applied the net proceeds from the issuance of the 8.95% notes and corporate cash to repurchase \$234.6 principal amount of our 5.5% notes due October 1, 2010 for a purchase price of \$242.8 plus accrued interest of \$3.7 and \$15.4 principal amount of our 4.6% notes due July 1, 2013 for a purchase price of \$14.6 plus accrued interest of \$0.1.

There were no borrowings outstanding under the \$400.0 unsecured five-year revolving credit facility at June 30, 2010. This facility contains covenants that are customary for such facilities including two financial covenants: the ratio of consolidated total debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) and the ratio of consolidated EBITDA to consolidated interest expense. We are in compliance with these covenants and expect to be in compliance for the remainder of the current facility which matures in June 2012.

The weighted-average interest rate on all of our debt was 6.79% and 5.34% as of June 30, 2010 and 2009, respectively. The weighted-average interest rate on short-term borrowings outstanding as of June 30, 2010 and 2009 was 1.16% and 1.79%, respectively.

8. ENVIRONMENTAL, CONTINGENCIES AND COMMITMENTS**Environmental Matters**

We are subject to substantial costs arising out of environmental laws and regulations, which include obligations to remove or limit the effects on the environment of the disposal or release of certain wastes or substances at various sites or to pay compensation to others for doing so.

As of June 30, 2010 and December 31, 2009, the aggregate environmental related accruals were \$99.2 and \$105.4, respectively. As of June 30, 2010 and December 31, 2009, \$5.5 of the above amounts were included in accrued expenses, with the remainder included in other noncurrent liabilities. Environmental remediation spending for the three months ended June 30, 2010 and 2009 was \$0.9 and \$0.9, respectively, and for the six months ended June 30, 2010 and 2009 was \$2.0 and \$1.7, respectively.

Table of Contents

Our process is to review our environmental remediation accruals quarterly and based on new information, may from time to time adjust our environmental related accruals. During the six months ended June 30, 2010, based on additional information generated by site evaluations, we increased our environmental related accruals by \$2.5, primarily related to operating sites in the U.S and Europe.

Our environmental related accruals can change substantially due to such factors as additional information on the nature or extent of contamination, methods of remediation required, changes in the apportionment of costs among responsible parties and other actions by governmental agencies or private parties or if we are named in a new matter and determine that an accrual needs to be provided or if we determine that we are not liable and no longer require an accrual.

A further discussion of environmental matters can be found in Note 11 of the Notes to the Consolidated Financial Statements contained in our 2009 Annual Report on Form 10-K.

Other Contingencies

We are the subject of numerous lawsuits and claims incidental to the conduct of our or certain of our predecessors' businesses, including lawsuits and claims relating to product liability, personal injury including asbestos, environmental, contractual, employment and intellectual property matters.

As of June 30, 2010 and December 31, 2009, the aggregate self-insured and insured contingent liability was \$60.0 and \$60.8, respectively, and the related insurance recovery receivable for the liability as well as claims for past payments was \$24.9 at June 30, 2010 and \$28.0 at December 31, 2009. The asbestos liability included in the above amounts at June 30, 2010 and December 31, 2009 was \$44.8 and \$45.0, respectively, and the insurance receivable related to the liability as well as claims for past payments was \$24.0 at June 30, 2010 and \$26.5 at December 31, 2009. We anticipate receiving a net tax benefit for payment of those claims for which full insurance recovery is not realized.

Asbestos

We, like many other industrial companies, have been named as one of hundreds of defendants in a number of lawsuits filed in the U.S. by persons alleging bodily injury from asbestos. The claimants allege exposure to asbestos at facilities that we own or formerly owned or from products that we formerly manufactured for specialized applications. Most of these cases involve numerous defendants, sometimes as many as several hundred. Historically, most of the closed asbestos claims against us have been dismissed without any indemnity payment by us; however, we can make no assurances that this pattern will continue.

The following table presents information about the number of claimants involved in asbestos claims with us:

	Six Months Ended June 30, 2010	Year Ended December 31, 2009
Number of claimants at beginning of period	8,000	8,100
Number of claimants associated with claims closed during period	(100)	(200)
Number of claimants associated with claims opened during period	0	100
Number of claimants at end of period	7,900	8,000

Numbers in the foregoing table are rounded to the nearest hundred and are based on information as received by us which may lag actual court filing dates by several months or more. Claims are recorded as closed when a claimant is dismissed or severed from a case. Claims are opened whenever a new claim is brought, including from a claimant previously dismissed or severed from another case.

During the third quarter of 2009, we completed an actuarial study of our asbestos related contingent liabilities and related insurance receivables. This study which updated our last study prepared in the third quarter of 2006, is based on, among other things, the incidence and nature of historical claims data through June 30, 2009, the incidence of malignancy claims, the severity of indemnity payments for malignancy and non-malignancy claims, dismissal rates by claim type, estimated future claim frequency, settlement values and reserves, and expected average insurance recovery rates by claim type.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

As a result of our findings, we recorded a decrease of \$5.0 to our self insured and insured contingent liabilities for indemnity costs for pending and anticipated probable future claims and recorded a decrease of \$4.9 related to receivables for probable insurance recoveries for these pending and future claims. The reserve decrease is attributable to significantly lower projected claim filings offset by more severe malignancy rates and settlement value projections. The decrease in the receivable is a result of the lower gross liability and a shift in the types of future claims expected. Overall, we expect to recover approximately 48% of our future indemnity costs. We have completed coverage in place agreements with most of our larger insurance carriers.

-13-

Table of Contents

It should be noted that the ultimate liability and related insurance recovery for all pending and anticipated future claims cannot be determined with certainty due to the difficulty of forecasting the numerous variables that can affect the amount of the liability and insurance recovery. These variables include but are not limited to: (i) significant changes in the number of future claims; (ii) significant changes in the average cost of resolving claims; (iii) changes in the nature of claims received; (iv) changes in the laws applicable to these claims; and (v) financial viability of co-defendants and insurers.

Lead Pigment

Over the past 15 years we have been named as defendants in more than fifty cases in the U.S. in which plaintiffs assert claims for personal injury, property damage, and other claims for relief relating to one or more kinds of lead pigment that were used as an ingredient decades ago in paint for use in buildings. Eight cases remain outstanding. The different suits were brought by government entities and/or individual plaintiffs, on behalf of themselves and others. The suits variously sought compensatory and punitive damages and/or injunctive relief, including funds for the cost of monitoring, detecting and removing lead based paint from buildings and for medical monitoring; for personal injuries allegedly caused by ingestion of lead based paint; and plaintiffs' attorneys' fees. We settled one of these cases in 2005 for an immaterial amount in order to avoid litigation costs. In all of the others, we prevailed in court or were dismissed as a defendant. We believe that the eight remaining suits against us are without merit, and we are vigorously defending them.

Seven of the remaining lead suits are for personal injury claims and have been filed against us in Wisconsin. In July 2005, the Supreme Court of Wisconsin held in a case in which we were one of several defendants that Wisconsin's risk contribution doctrine applies to bodily injury cases against manufacturers of white lead pigment. Under this doctrine, manufacturers of white lead pigment may be liable for injuries caused by white lead pigment based on their past market shares unless they can prove they are not responsible for the white lead pigment which caused the injury in question. Seven other courts have previously rejected the applicability of this and similar doctrines to white lead pigment. The trial court's dismissal of the plaintiff's strict liability and negligent design defect causes of action for white lead carbonate in the case styled *Ruben Godoy et al v. E.I DuPont de Nemours et al.*, one of the Wisconsin lead cases, was affirmed by the Wisconsin Court of Appeals in October 2007 and by the Wisconsin Supreme Court in July 2009. The decision in this case together with our non-existent or diminutive market share reinforces our belief that we have no liability in any of the Wisconsin cases, and accordingly, we have not recorded a loss contingency.

We have access to a substantial amount of primary and excess general liability insurance for certain lead pigment related claims and believe these policies are available to cover a significant portion of both our defense costs and indemnity costs, if any, for certain lead pigment related claims. We currently have agreements with two of our insurers which provide that they will pay for approximately fifty percent (50%) of our defense costs associated with certain lead pigment related claims.

Other

Periodically, we enter into settlement discussions for lawsuits or claims for which we have meritorious defenses and for which an unfavorable outcome against us is not probable. In such instances, no loss contingency is recorded since a loss is not probable and it is our policy to expense defense costs as incurred. Typically, we consider these types of settlements in fairly limited circumstances usually related to the avoidance of future defense costs and/or the elimination of any risk of an unfavorable outcome. Such settlements, if any, are recorded when it is probable a liability has been incurred, typically upon entering into a settlement agreement.

While it is not feasible to predict the outcome of all pending environmental matters, lawsuits and claims, it is reasonably possible that there will be a necessity for future provisions for costs for environmental matters and for other contingent liabilities that we believe, will not have a material adverse effect on our consolidated financial position, but could be material to our consolidated results of operations or cash flows in any one accounting period. We cannot estimate any additional amount of loss or range of loss in excess of the recorded amounts. Moreover, many of these liabilities are paid over an extended period, and the timing of such payments cannot be predicted with any certainty.

From time to time, we are also included in legal proceedings as a plaintiff involving tax, contract, patent protection, environmental and other legal matters. Gain contingencies related to these matters, if any, are recorded when they are realized.

A further discussion of other contingencies can be found in Note 11 of the Notes to the Consolidated Financial Statements contained in our 2009 Annual Report on Form 10-K.

Commitments

We frequently enter into long-term contracts with customers with terms that vary depending on specific industry practices. Our business is not substantially dependent on any single contract or any series of related contracts. Descriptions of our significant sales contracts at December 31,

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

2009 are set forth in Note 11 of the Notes to Consolidated Financial Statements contained in our 2009 Annual Report on Form 10-K.

Table of Contents**9. COMPREHENSIVE INCOME**

The components of comprehensive income, which represents the change in equity from non-owner sources, for the three and six months ended June 30, 2010 and 2009 are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
Net earnings/(loss)	\$ 62.4	\$ (24.4)	88.1	(24.3)
Other comprehensive income (loss):				
Accumulated pension liability, net of tax	1.5	0.8	10.3	1.5
Unrealized (losses)/gains on cash flow hedges, net of tax	4.5	(1.6)	0.4	(10.1)
Foreign currency translation adjustments	(62.1)	82.3	(89.8)	25.0
Comprehensive income/(loss)	\$ 6.3	\$ 57.1	\$ 9.0	\$ (7.9)
Comprehensive income attributable to noncontrolling interest	0.6	0.5	1.7	0.5
Comprehensive income/(loss) attributable to Cyttec Industries Inc.	\$ 5.7	\$ 56.6	\$ 7.3	\$ (8.4)

10. INCOME TAXES

The effective income tax rate for the three and six months ended June 30, 2010 was a tax provision of 27.8% (\$24.0) and 35.4% (\$48.4), respectively, compared to a tax benefit of 31.8% (\$11.4) and 29.9% (\$10.4) for the three and six months ended June 30, 2009. The 2010 effective tax rate for the year-to-date period was unfavorably impacted by an \$8.3 charge to tax expense related to the enactment of U.S. health care legislation (as further discussed below), partially offset by discrete \$2.9 tax benefits in the second quarter of 2010 primarily attributable to the remeasurement of the future utilization of deferred tax assets in a European tax jurisdiction. The underlying estimated annual income tax rate for the six months ended June 30, 2010 was 31.3% (excluding accrued interest on unrecognized tax benefits) with an underlying tax rate of 31.8% including such interest.

For the first six months ended June 30, 2009, the rate was unfavorably impacted by the zero tax benefit given to restructuring costs related to our decision to exit our polyurethane product line operations in Asia. The effective income tax rate for the first six months of 2009 also includes a limited tax benefit for other restructuring charges.

The *Medicare Prescription Drug, Improvement and Modernization Act of 2003* established a U.S. Medicare prescription drug benefit and a tax-free federal subsidy to companies that sponsored retiree health care plans. Pursuant to *The Patient Protection and Affordable Care Act*, as signed into law on March 23, 2010, as amended by the *Health Care and Education Reconciliation Act of 2010* on March 30, 2010, the U.S. tax deductible prescription drug costs will now be reduced by the aforementioned federal subsidy. The impact of this legislation will reduce the future tax deductions with respect to the Company's prescription drug costs. Accordingly, we recorded an \$8.3 charge to tax expense from continuing operations in the first quarter 2010 to reflect the reduction in the related deferred tax asset.

As of June 30, 2010, the amount of unrecognized tax benefits is \$37.8 (gross) of which \$19.2 would impact our effective tax rate, if recognized. The amount of unrecognized tax benefits at December 31, 2009 was \$37.9 (gross) of which \$19.8 would impact our effective tax rate, if recognized.

We recognize interest and penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of income. We had recorded a liability for the payment of interest (gross), of approximately \$6.9 as of December 31, 2009, which decreased \$0.5 due to current year tax activity and the impact of foreign exchange, thus resulting in a liability for the payment of interest of \$6.4 (gross) as of June 30, 2010.

11. OTHER FINANCIAL INFORMATION

On April 22, 2010, our Board of Directors declared a \$0.0125 per common share cash dividend, payable on May 25, 2010 to shareholders of record as of May 10, 2010. Cash dividends paid in the second quarter of 2010 and 2009 were \$0.6 and \$0.6, respectively, and for the six months

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

ended June 30, 2010 and 2009 were \$2.5 and \$6.5, respectively. Dividends paid in the first six months of 2010 include \$1.3 paid by a majority owned subsidiary to its minority shareholder. On July 20, 2010 the Board of Directors declared a \$0.0125 per common share cash dividend, payable on August 25, 2010 to shareholders of record as of August 10, 2010.

-15-

Table of Contents

Income taxes paid for the six months ended June 30, 2010 and 2009 were \$27.0 and \$21.9, respectively. Interest paid for the six months ended June 30, 2010 and 2009 was \$15.8 and \$17.2, respectively. Interest income for the six months ended June 30, 2010 and 2009 was \$3.3 and \$3.4, respectively.

During the first quarter of 2010, we sold our real estate at an inactive site for \$2.5 of which \$0.5 was received in cash and \$2.0 represents a promissory note from the purchaser. The net gain of \$2.3 from this sale is recorded in other expense, net in the accompanying statements of income.

12. SEGMENT INFORMATION

Summarized segment information for our five segments for the three and six months ended June 30 is as follows:

	Three months ended June 30,		Six months ended June 30,	
	2010	2009	2010	2009
Net Sales:				
Coating Resins	\$ 368.9	\$ 295.3	\$ 710.4	\$ 542.0
Additive Technologies				
Sales to external customers	66.1	62.9	128.4	113.8
Intersegment sales	0.2	0.2	0.5	0.2
In Process Separation	70.7	58.0	135.8	113.9
Engineered Materials	196.3	178.3	374.0	369.9
Building Block Chemicals				
Sales to external customers	171.9	90.8	312.1	157.7
Intersegment sales	6.0	6.8	13.0	11.7
Net sales from segments	880.1	692.3	1,674.2	1,309.2
Elimination of intersegment revenue	(6.2)	(7.0)	(13.5)	(11.9)
Total consolidated net sales	\$ 873.9	\$ 685.3	\$ 1,660.7	\$ 1,297.3

	Three months ended June 30,				Six months ended June 30,			
	2010	% of Sales	2009	% of Sales	2010	% of Sales	2009	% of Sales
Earnings/(loss) from operations:								
Coating Resins	\$ 28.0	8%	\$ (19.2)	(7)%	\$ 44.7	6%	\$ (39.5)	(7)%
Additive Technologies	10.7	16%	3.1	5%	19.0	15%	3.6	3%
In Process Separation	14.3	20%	2.1	4%	29.2	22%	6.8	6%
Engineered Materials	38.6	20%	22.1	12%	59.6	16%	55.2	15%
Building Block Chemicals	15.0	9%	1.9	2%	19.1	6%	5.1	3%
Earnings from segments	106.6	12%	10.0	1%	171.6	10%	31.2	2%
Corporate and Unallocated, net (1)	(10.9)		(40.9)		(16.7)		(52.4)	
Total earnings/(loss) from operations	\$ 95.7	11%	\$ (30.9)	(5)%	\$ 154.9	9%	\$ (21.2)	(2)%

- (1) For the three and six months ended June 30, 2010, Corporate and Unallocated includes pre-tax charges of \$4.5 and \$4.1, respectively, related to the exit of certain phosphorus derivative products and net favorable adjustments of previously recorded restructuring liabilities. For the three and six months ended June 30, 2009, Corporate and Unallocated includes pre-tax charges of \$34.2 and \$37.4, respectively, for various manufacturing and organizational restructuring initiatives across our Specialty Chemical and Engineered Materials segments

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

and organizational restructuring activities within corporate operations. Also for the three and six months ended June 30, 2009, Corporate and Unallocated includes pre-tax net charges of \$1.4 and \$1.4, respectively, related to the exit of our polyurethane product line in Europe and Asia.

-16-

Table of Contents**13. GOODWILL AND OTHER ACQUISITION INTANGIBLES**

The following is the activity in the goodwill balances for each segment.

	Coating Resins	Additive Technologies	In Process Separation	Engineered Materials	Total
Balance, December 31, 2009:					
Goodwill	762.2	19.6	53.2	256.8	1,091.8
Accumulated impairment charges	(389.9)	0.0	0.0	0.0	(389.9)
	\$ 372.3	\$ 19.6	\$ 53.2	\$ 256.8	\$ 701.9
Currency exchange:					
Goodwill	(77.0)	0.0	(1.2)	(2.5)	(80.7)
Accumulated impairment charges	38.5	0.0	0.0	0.0	38.5
	(38.5)	0.0	(1.2)	(2.5)	(42.2)
Balance, June 30, 2010:					
Goodwill	685.2	19.6	52.0	254.3	1,011.1
Accumulated impairment charges	(351.4)	0.0	0.0	0.0	(351.4)
	\$ 333.8	\$ 19.6	\$ 52.0	\$ 254.3	\$ 659.7

Other acquisition intangibles consisted of the following major classes:

	Weighted Average Useful Life (years)	Gross Carrying Value		Accumulated Amortization		Net Carrying Value	
		June 30, 2010	December 31, 2009	June 30, 2010	December 31, 2009	June 30, 2010	December 31, 2009
Technology-based	16.2	\$ 53.0	\$ 55.9	\$ (32.5)	\$ (32.3)	\$ 20.5	\$ 23.6
Marketing-related	< 2.0	1.8	2.1	(1.8)	(2.1)	0.0	0.0
Marketing-related	15.5	61.1	65.0	(25.8)	(25.6)	35.3	39.4
Marketing-related	40.0	40.6	47.5	(4.1)	(4.2)	36.5	43.3
Customer-related	15.0	402.4	443.8	(150.4)	(150.6)	252.0	293.2
Total		\$ 558.9	\$ 614.3	\$ (214.6)	\$ (214.8)	\$ 344.3	\$ 399.5

Amortization of acquisition intangibles for the three months ended June 30, 2010 and 2009 was \$9.0 and \$9.4, respectively, and for the six months ended June 30, 2010 and 2009 was \$18.5 and \$18.6, respectively.

Assuming no change in the gross carrying amount of acquisition intangibles and the 2010 average currency exchange rates remain constant, the estimated future amortization expense for the next five years are as follows:

	2010	2011	2012	2013	2014	2015
Intangibles Amortization Expense	\$ 37.1	\$ 37.0	\$ 36.9	\$ 36.3	\$ 35.9	\$ 35.8

14. DERIVATIVE FINANCIAL INSTRUMENTS AND COMMODITY HEDGING ACTIVITIES**Foreign Currency Derivative and Hedging Activities**

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

We periodically enter into currency forward contracts primarily to hedge currency fluctuations of transactions denominated in currencies other than the functional currency of the respective entity. At June 30, 2010, the principal transactions hedged involved accounts receivable, accounts payable and intercompany loans. When hedging currency exposures, our practice is to economically hedge such exposures with forward contracts denominated in the same currency and with similar critical terms as the underlying exposure, and therefore, the instruments are effective at generating offsetting changes in the fair value, cash flows or future earnings of the hedged item or transaction. The fair values of forward contracts are calculated each period. These forward contracts are not defined as hedging instruments therefore, all changes in fair values are reported in other expense, net.

-17-

Table of Contents

At June 30, 2010, net contractual amounts of forward contracts outstanding translated into U. S. dollars (USD) amount to \$143.7. Of this total, \$121.3 was attributed to the exposure in forward selling/purchase of USD. The remaining \$22.4 was attributable to the exposure in forward selling/purchase of Euros, translated into USD equivalent amounts. The net (unfavorable)/favorable fair values of currency contracts, based on forward exchange rates at June 30, 2010 and December 31, 2009 were (\$3.7) and \$0.5, respectively.

We use cross currency swaps to hedge the changes in the cash flows of certain Euro denominated intercompany loans receivable (Euro loans) held by U.S. entities. The loan amounts are 207.9 and 207.9 due October 1, 2010 and October 1, 2015, respectively. Since the loans are denominated in Euros, we have foreign exchange exposure upon remeasurement to USD. We originally hedged this foreign exchange exposure by entering into two cross currency swaps each with notional amounts of 207.9 (\$250.0) that settle on October 1, 2010 (five year swaps) and October 1, 2015 (ten year swaps), respectively. At the initial principal exchange, we paid \$500.0 and received 415.8 from counterparties. At the final exchanges on each of October 1, 2010 and October 1, 2015, we will pay 207.9 and receive \$250.0. The swaps have fixed interest rates on both legs. On the five year swaps, we pay 3.78% interest per annum on the Euro notional amount and we receive 5.5% interest per annum on the USD notional amount. On the ten year swaps, we pay 4.52% interest per annum on the Euro notional amount and we receive 6.0% interest per annum on the USD notional amount. The interest payment dates (April 1 and October 1) and Euro rates coincide with the Euro loans.

The five and ten year swaps fix the U.S. dollar equivalent cash flows of the Euro loans and eliminate foreign exchange variability since the notional amounts of the swaps equal that of the loans, and all cash flow dates and interest rates coincide between the swaps and the loans, therefore no ineffectiveness is expected. At inception, the five and ten year swaps were designated as cash flow hedges of the Euro loans. In November 2008, the five year swaps were de-designated as cash flow hedges, due to our decision to execute new off-setting cross currency swaps (two year swaps) to lock-in the Euro forward exchange rate for the principal exchange on the five year swaps due on October 1, 2010. A net after-tax credit of \$5.5 remained in other comprehensive income on the de-designation date representing the unrealized gain associated with the five year swaps. As it is probable that the original hedged forecasted transaction will occur, this \$5.5 of unrealized gains is being reclassified into earnings on a straight line basis over the remaining life of the previously hedged transaction, which was 23 months as of the de-designation date. The remaining amount of other comprehensive income at June 30, 2010 which will be amortized to income in the future is \$0.7, all of which will be amortized over the next three months.

The two year swaps cover an identical notional amount of 207.9 and also call for a semi-annual exchange of fixed Euro interest receipts for fixed USD interest payments. With respect to the two year swaps, we will receive 3.78% per annum on the Euro notional amount and will pay 3.69% per annum on the USD notional amount on each April 1 and October 1, through the maturity date of the two year swaps, which is also on October 1, 2010. The two year swaps are not designated as cash flow hedges, therefore all changes in fair value are reported in interest expense, net, and other expense, net.

All cross currency swaps are recorded at fair value as either assets or liabilities. We accrue the periodic net swap interest payments due each period in the consolidated income statement. Each period we record the change in the fair value of the ten year swaps in accumulated other comprehensive income. For the ten year swaps, we reclassify an amount out of accumulated other comprehensive income to the income statement to offset the foreign currency gain or loss on the remeasurement to USD of the Euro intercompany loans. The amount of such reclassification will depend on changes in the USD/Euro exchange rate occurring during the period. We accounted for the five year swaps in this manner until de-designation as cash flow hedges in November 2008. The fair value of the two year swaps and prospectively, upon de-designation, the five year swaps, is calculated each period with changes in fair value reported in interest expense, net, and other (expense)/income, net. We expect the earnings impact related to future changes in the fair value of the two year swaps to substantially offset the earnings impact related to future changes in the fair value of the five year swaps. We monitor the counterparty credit risk and the continued probability of the hedged cash flows as to amount and timing.

At June 30, 2010, the (unfavorable)/ favorable fair values of the two, five, and ten year swaps were \$(9.6), \$(2.4), and \$6.5, respectively, and at December 31, 2009, the favorable/(unfavorable) fair values of the two, five, and ten year swaps were \$34.8, \$(44.7), and \$(41.6), respectively.

Commodity Derivative and Hedging Activities

We purchase natural gas for utility consumption at our manufacturing facilities and therefore, our overall profitability and operating cash flows are exposed to the variability in the market price. To partially eliminate this variability, we use natural gas forward purchase contracts to hedge a portion of our utility requirements at certain of our North American manufacturing facilities. These forward contracts, which are highly effective at achieving offsetting cash flows of the underlying natural gas purchases, have been designated as cash flow hedges of our forecasted natural gas purchases and are reported on the consolidated balance sheets at fair value in other assets/liabilities, with the effective portion of the fair value of the forward contract included in accumulated other comprehensive income/(loss) on an after-tax basis. Any ineffectiveness, which represents the amount by which the cumulative change in the cash flows of the forward contract is not completely offset by the cumulative change in the cash flows of the hedged transaction is recognized in other (expense)/income, net in the current period. During the six months ended June 30, 2010 and June 30, 2009 there were no significant gains or losses reported in earnings for ineffectiveness. Gains and losses are

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

reclassified into earnings, as a component of manufacturing cost of sales, in the period the hedged natural gas purchases affect earnings. If the derivative is no longer highly effective in achieving offsetting cash flows, subsequent changes in fair value are recorded in other expense, net. If the hedging relationship is terminated and the originally hedged transaction remains probable of occurring, the unrealized gain or loss associated with forward contracts remains in accumulated other comprehensive income and is recognized in earnings as a component of cost of sales in the period the originally hedged natural gas purchase affects earnings. If the forecasted transaction is no longer probable of occurring we recognize the related gain or loss in other expense, net in that period.

-18-

Table of Contents

Generally, short-term (one to three months) natural gas usage requirements are hedged up to 90% with a gradual decrease to 10% for the natural gas requirements extending out to twelve months. At June 30, 2010, we held natural gas forwards to purchase approximately 2,300,000 MMBtu of gas with an unfavorable fair value of \$1.0 included in accrued expenses, which will be reclassified into Manufacturing Cost of Sales through May 2011 as the hedged natural gas purchases affect earnings.

At June 30, 2010, we did not have derivative instruments that contained credit-related-risk contingent features or provisions that would trigger immediate settlement or require us to post collateral to our counterparties. Also as of June 30, 2010, we did not have any significant concentration of credit risk arising from our derivative instruments.

Net Investment Hedge Activities

The value of one of our U.S. subsidiaries' net investment in our Belgium-based subsidiary, Cytec Surface Specialties SA/NV (our largest Euro functional currency subsidiary), is affected by foreign exchange movements in the U.S. dollar value of the Euro. To hedge this foreign currency exposure inherent in a net investment in such foreign operation, a portion of the intercompany Euro denominated loans payable of one of our U.S. subsidiaries is designated as a net investment hedge of Cytec Surface Specialties SA/NV. The portion of the remeasurement of the intercompany loan to the U.S. dollar that relates to the amount designated as a hedge of our net investment is recorded as a translation adjustment within accumulated other comprehensive income (loss)/gain. From time to time we also enter into designated forward Euro contracts to adjust the amount of the net investment hedge. At June 30, 2010, we had no designated forward contracts. For the six months ended June 30, 2010 and 2009, \$13.1 and \$(1.1), net of tax, respectively, related to remeasurement of intercompany loans designated as a net investment hedge was recorded as a translation adjustment within accumulated other comprehensive income gain/(loss), respectively.

Following is a summary of the impact of derivative instruments on our consolidated balance sheets and statements of income:

	Asset Derivatives				Liability Derivatives			
	June 30, 2010		December 31, 2009		June 30, 2010		December 31, 2009	
	Balance Sheet Location	Fair Value	Balance Sheet Location	Fair Value	Balance Sheet Location	Fair Value	Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:								
Natural Gas Forwards			Other current assets	\$ 0.3	Accrued expenses	\$ 1.0		
Cross currency swaps (1)	Other current assets	\$ 0.9	Other current assets	0.4			Other noncurrent liabilities	\$ 42.0
Cross currency swaps (1)	Other assets	5.6						
Total derivatives designated as hedging instruments:		\$ 6.5		\$ 0.7		\$ 1.0		\$ 42.0
Derivatives not designated as hedging instruments:								
Cross currency swaps (2)	Other current assets	\$ 1.0	Currency Swap receivable	\$ 34.4	Currency Swap payable	\$ 13.0	Currency Swap payable	\$ 45.3
			Other current assets	1.0				
Foreign currency forwards	Other current assets	1.8	Other current assets	2.4	Accrued expenses	5.5	Accrued expenses	1.9
Total derivatives not designated as hedging instruments:		\$ 2.8		\$ 37.8		\$ 18.5		\$ 47.2
Total derivatives		\$ 9.3		\$ 38.5		\$ 19.5		\$ 89.2

Table of Contents**Derivatives**

in Cash			Location of Gain or (Loss) Recognized from Accumulated OCI into Income (Effective Portion)	Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective and Excluded from Effectiveness Testing)	Amount of Gain or (Loss) Recognized in Income on Derivative		
	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	Income (Effective Portion)				Amount Excluded from Effectiveness Testing	Amount Excluded from Effectiveness Testing	
Flow	Three Months Ended June 30		Three Months Ended June 30		Three Months Ended June 30			
Hedging	2010	2009	2010	2009	2010	2009	2010	2009
Natural Gas Forwards	\$ 0.5	\$ (0.3)	Manufacturing cost of sales	(1.2)	\$ (9.7)	Other expense, net	\$ 0.0	\$ 0.0
Cross currency swaps (2)	20.2	(14.7)	Other expense, net	26.6	(17.5)			
Total	\$ 20.7	\$ (15.0)		\$ 25.4	\$ (27.2)		\$ 0.0	\$ 0.0

Derivatives

in Cash			Location of Gain or (Loss) Recognized from Accumulated OCI into Income (Effective Portion)	Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective and Excluded from Effectiveness Testing)	Amount of Gain or (Loss) Recognized in Income on Derivative		
	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	Income (Effective Portion)				Amount Excluded from Effectiveness Testing	Amount Excluded from Effectiveness Testing	
Flow	Six Months Ended June 30		Six Months Ended June 30		Six Months Ended June 30			
Hedging	2010	2009	2010	2009	2010	2009	2010	2009
Natural Gas Forwards	\$ (2.0)	\$ (4.2)	Manufacturing cost of sales	\$ (2.3)	\$ (15.3)	Other expense, net	\$ 0.0	\$ 0.1
Cross currency swaps (2)	29.5	(12.5)	Other expense, net	43.8	0.5			
Total	\$ 27.5	\$ (16.7)		\$ 41.5	\$ (14.8)		\$ 0.0	\$ 0.1

Table of Contents

Derivatives not Designated as Hedging Instruments:	Location of Gain or (Loss)	Amount of Gain or (Loss)	
	Recognized in Income on Derivative	Recognized in Income on Derivative	
		Three Months Ended June 30 2010	2009
Foreign currency forwards	Other expense, net	\$ (7.6)	\$ 7.0
Cross currency swaps (2)	Other expense, net	(1.0)	(1.1)
Cross currency swaps (2)	Interest expense, net	1.0	1.0
Cross currency swaps (3)	Interest expense, net	1.2	1.2
Total		\$ (6.4)	\$ 8.1

Derivatives not Designated as Hedging Instruments:	Location of Gain or (Loss)	Amount of Gain or (Loss)	
	Recognized in Income on Derivative	Recognized in Income on Derivative	
		Six Months Ended June 30 2010	2009
Foreign currency forwards	Other expense, net	\$ (9.2)	\$ 8.5
Cross currency swaps (2)	Other expense, net	(2.0)	(1.9)
Cross currency swaps (2)	Interest expense, net	2.0	